Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : INCY crawled time : 17:00 save search
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
Published: 2024-04-01 (Crawled : 17:00) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.6%
H: 0.0%
C: -0.58%
license collaboration asia agreement
AnHeart Therapeutics and Innovent Announce China’s NMPA Has Accepted a New Drug Application for Taletrectinib (ROS1 Inhibitor)
Published: 2023-11-22 (Crawled : 17:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.74%
H: 0.71%
C: 0.71%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.34%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.56%
H: 1.06%
C: -0.24%
drug application therapeutics
New Long-Term Data from Incyte Phase 3 TRuE-V Program Demonstrates Efficacy of Continued Treatment with Opzelura® (Ruxolitinib) Cream in Nonsegmental Vitiligo Patients
Published: 2023-10-11 (Crawled : 17:00) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.45%
H: 0.52%
C: -0.94%
opzelura treatment program
Pancreatic Cancer Battle Boosted by $200M VC Firm
Published: 2023-09-19 (Crawled : 17:00) - prnewswire.com
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: -1.47%
H: 4.98%
C: 3.98%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -0.13%
H: 2.0%
C: 1.83%
MACK 4 | $14.72 0.27% 0.27% 76K
|
Health Technology
|
| O: -0.41%
H: 0.9%
C: 0.74%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.03%
H: 2.18%
C: 1.8%
BNTX | $86.82 0.75% 0.75% 1.6M
|
Health Technology
|
| O: -0.01%
H: 1.99%
C: 1.28%
cancer pancreatic
The Worldwide Alopecia Treatment Industry is Projected to Reach $6.2 Billion by 202
Published: 2023-01-10 (Crawled : 17:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: -0.52%
H: 1.79%
C: 1.73%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 0.58%
H: 0.39%
C: 0.03%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.24%
H: 1.21%
C: 1.07%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.1%
H: 2.05%
C: 0.82%
treatment
Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (DREAMS-1) of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes
Published: 2023-01-09 (Crawled : 17:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.38%
H: 0.28%
C: 0.28%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.29%
H: 0.27%
C: -3.89%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.82%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.02%
H: 0.36%
C: -2.56%
ibi362 chinese diabetes study
M&A Frenzy: Incyte & Villaris, AmplifyBio & PACT, Estrella Earns Nasdaq Listing
Published: 2022-10-03 (Crawled : 17:00) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.74%
H: 2.89%
C: 2.53%
nasdaq
Ascentage Pharma and Innovent Announce the China NMPA Accepted and Granted Priority Review Designation to a New Drug Application for Olverembatinib for the Treatment of Drug-Resistant CML
Published: 2022-07-19 (Crawled : 17:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.72%
H: 1.02%
C: 0.65%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.83%
H: 0.0%
C: 0.0%
treatment designation pharma drug application granted review china
IASO Bio and Innovent Jointly Announce the NMPA Acceptance of the New Drug Application for Equecabtagene Autoleucel for the Treatment of Relapsed and/or Refractory Multiple Myeloma
Published: 2022-06-02 (Crawled : 17:00) - biospace.com/
SANA | $7.605 -1.62% -1.64% 3.4M
|
|
| O: -6.1%
H: 9.2%
C: 8.6%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.9%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.4%
H: 0.25%
C: -0.07%
treatment drug application
Breast Cancer Treatment Advancements Emerge After New Study Finds Global Deaths Increased in 2019
Published: 2022-01-14 (Crawled : 17:00) - prnewswire.com
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: -0.21%
H: 0.98%
C: 0.98%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -1.01%
H: 0.0%
C: 0.0%
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 0.65%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.17%
H: 0.0%
C: 0.0%
treatment cancer breast cancer merge
FDA broadens existing emergency use of Lilly and Incyte's baricitinib in patients hospitalized with COVID-19 requiring oxygen
Published: 2021-07-29 (Crawled : 17:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.4%
H: 0.3%
C: -0.88%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.64%
H: 0.14%
C: -1.41%
covid baricitinib fda oxygen merge
Scandal Watch: Elizabeth Holmes Appears in Court, Opioid Distributors on Tria...
Published: 2021-05-05 (Crawled : 17:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.16%
H: 0.0%
C: -0.26%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.9%
H: 1.68%
C: -0.59%
opioid
Scandal Watch: Elizabeth Holmes Appears in Court, Opioid Distributors on Trial and More
Published: 2021-05-05 (Crawled : 17:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.16%
H: 0.0%
C: -0.26%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.9%
H: 1.68%
C: -0.59%
opioid trial
OLUMIANT® Showed Significant Improvements in the Severity and Extent of Atopic Dermatitis and Other Patient-Reported Outcomes in Phase 3 Study Analyses
Published: 2021-04-23 (Crawled : 17:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.01%
H: 1.12%
C: 0.9%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.5%
H: 1.3%
C: 1.16%
dermatitis phase 3 atopic dermatitis
Global Kinase Inhibitors in Autoimmune Diseases Market to Continue on Growth Trajectory with 19.17% CAGR During the Study Period (2018-2030), Asserts DelveInsight
Published: 2021-04-19 (Crawled : 17:00) - prnewswire.com
MDT | $79.48 0.37% -0.29% 6.7M
|
Health Technology
|
| O: -0.44%
H: 0.74%
C: 0.61%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.16%
H: 0.38%
C: 0.12%
EW | $85.94 -0.59% 0.0% 3.9M
|
Health Technology
|
| O: -0.73%
H: 0.75%
C: 0.22%
BSX | $67.33 -0.13% -0.31% 7M
|
Health Technology
|
| O: -0.29%
H: 0.44%
C: 0.22%
NUVA | $39.75 -2.24% -2.29% 0
|
Health Technology
|
| O: -0.07%
H: 0.0%
C: -0.32%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.13%
H: 1.12%
C: -0.14%
GLPG | News | $29.095 0.64% 0.64% 87K
|
Health Technology
|
| O: 0.58%
H: 0.21%
C: -0.98%
disease growth
Incyte Announces Acceptance and Priority Review of NDA for Ruxolitinib Cream for Atopic Dermatitis
Published: 2021-02-19 (Crawled : 17:00) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.58%
H: 0.56%
C: -1.8%
dermatitis atopic dermatitis
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.